Why the study?
Knowledge on risk predictors of incident HF in T2D is crucial, yet the diagnostic and prognostic performance of established cardiovascular biomarkers may be modified by T2D.
This position statement from the Heart Failure Association of the ESC summarizes current evidence and gaps regarding the use of biomarkers to predict incident heart failure and cardiovascular events in patients with type 2 diabetes.
Highlights evidence gaps in T2D biomarker use for HF prediction; leaves open prospective validation before clinical integration.
Knowledge on risk predictors of incident heart failure (HF) in patients with type 2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognized as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established cardiovascular biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and cardiovascular events in patients with T2D and in those with established HF and T2D.
No takes yet. Share an insight, caveat, or question.
Seferović et al. (2022) conducted a review in Type 2 diabetes and heart failure. Biomarkers was evaluated. This position paper summarizes current knowledge and evidence gaps regarding the use of various biomarkers for predicting incident heart failure and cardiovascular events in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: